Lamotrigine vs Levetiracetam

The SANAD trials provide the strongest comparative evidence ^[3]. SANAD-I found lamotrigine was the best overall treatment for focal epilepsy, superior to carbamazepine in terms of time to treatment failure. For generalized epilepsy, both lamotrigine and levetiracetam are effective, though valproic acid remains the gold standard ^[3].

Levetiracetam has shown efficacy as both monotherapy and adjunctive therapy for focal seizures, and as adjunctive therapy for generalized tonic-clonic seizures and myoclonic seizures ^[2]. Its IV formulation makes it useful when rapid AED loading is needed.

Lamotrigine is effective for focal seizures, generalized tonic-clonic seizures, and absence seizures ^[1]. Its dual utility as a mood stabilizer makes it particularly valuable for patients with comorbid bipolar disorder or mood instability ^[1].

Both have broad-spectrum activity, but lamotrigine should be used cautiously in myoclonic epilepsies where it may worsen myoclonus in some patients ^[1].

Levetiracetam's most significant side effect is behavioral: irritability, agitation, hostility, and mood changes occur in 5-15% of patients ^[2]. These psychiatric effects (sometimes called "Keppra rage") can be distressing and are a leading cause of discontinuation ^[2]. Other common effects include somnolence (15%), dizziness, fatigue, and headache ^[2].

Lamotrigine's most serious side effect is skin rash, including rare but potentially life-threatening Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), occurring in approximately 0.3-0.8% of adults ^[1]. The risk is minimized by very slow dose titration (starting at 25 mg/day and increasing every 2 weeks) ^[1]. This mandatory slow titration is a practical disadvantage. Other common effects include headache, dizziness, diplopia (double vision), and nausea ^[1].

Lamotrigine is generally weight-neutral and has mood-stabilizing effects that many patients find beneficial ^[1]. Levetiracetam is also weight-neutral but can worsen depression and anxiety in susceptible individuals ^[2].

Both are considered safer in pregnancy compared to valproic acid and topiramate, with lamotrigine having one of the largest pregnancy safety databases among AEDs ^[4].

Both are available as affordable generics. Lamotrigine costs $10-$30 per month ^[5]. Levetiracetam costs $10-$25 per month ^[5]. Both are widely covered by insurance.

Levetiracetam can be started at a therapeutic dose and titrated quickly (days to weeks) ^[2]. Lamotrigine requires very slow titration over 6-8 weeks to minimize rash risk, which delays reaching a therapeutic dose ^[1]. Levetiracetam is available in oral and IV formulations; lamotrigine is oral only ^[1][2]. Both are typically dosed twice daily. Levetiracetam's ability to reach therapeutic doses quickly is a significant advantage when prompt seizure control is needed.

Levetiracetam may be preferred when rapid dose titration is needed, for patients who need IV formulation, when drug interactions must be minimized, and for patients without mood or behavioral concerns ^[2].

Lamotrigine may be preferred for patients with comorbid bipolar disorder or mood instability, those who experience behavioral side effects from levetiracetam, and women of childbearing age (favorable pregnancy data) ^[1][4].

Both are excellent first-line AEDs for focal epilepsy. The decision often comes down to the need for speed (levetiracetam) versus mood/behavioral considerations (lamotrigine) ^[3].

This information is for educational purposes only. Consult your neurologist for personalized epilepsy treatment.